222 related articles for article (PubMed ID: 37328939)
1. Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.
Patel SA
Leuk Lymphoma; 2023 Sep; 64(9):1503-1513. PubMed ID: 37328939
[TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
3. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract][Full Text] [Related]
4. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
6. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
8. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
9. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
Falini B
Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
[TBL] [Abstract][Full Text] [Related]
10. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
12. An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape.
Bystrom R; Levis MJ
Curr Oncol Rep; 2023 Apr; 25(4):369-378. PubMed ID: 36808557
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
14. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.
Tang F; Zhao X; Ruan G; Jiang Q; Jiang H; Xu L; Wang Y; Zhang X; Liu K; Huang X
Hematol Oncol; 2023 Oct; 41(4):733-742. PubMed ID: 37272204
[TBL] [Abstract][Full Text] [Related]
15. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
16. Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia.
Cumbo C; Minervini CF; Orsini P; Anelli L; Zagaria A; Minervini A; Coccaro N; Impera L; Tota G; Parciante E; Conserva MR; Spinelli O; Rambaldi A; Specchia G; Albano F
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835432
[TBL] [Abstract][Full Text] [Related]
17. [Research Advance of Gene Mutation and Targeted Drug Therapy in Childhood Acute Myeloid Leukemia --Review].
DU CK; Lu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):631-635. PubMed ID: 35396009
[TBL] [Abstract][Full Text] [Related]
18. Advances in the pharmacological management of acute myeloid leukemia in adults.
Numan Y; Abaza Y; Altman JK; Platanias LC
Expert Opin Pharmacother; 2022 Sep; 23(13):1535-1543. PubMed ID: 35938317
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS; Pratz KW; Lai C
J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
